List of Movantik drug patents

Movantik is owned by Redhill.

Movantik contains Naloxegol Oxalate.

Movantik has a total of 6 drug patents out of which 2 drug patents have expired.

Expired drug patents of Movantik are:

  • US8617530
  • US7662365

Movantik was authorised for market use on 16 September, 2014.

Movantik is available in tablet;oral dosage forms.

Movantik can be used as treatment of opioid-induced constipation.

The generics of Movantik are possible to be released after 02 April, 2032.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7662365 REDHILL Polymer conjugates of opioid antagonists
Oct, 2022

(3 months ago)

US7786133 REDHILL Chemically modified small molecules
Sep, 2028

(5 years from now)

US9012469 REDHILL Crystalline naloxol-peg conjugate
Apr, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617530 REDHILL Polymer conjugates of opioid antagonists
Oct, 2022

(3 months ago)

US7056500 REDHILL Polymer conjugates of opioid antagonists
Jun, 2024

(1 year, 5 months from now)

US8067431 REDHILL Chemically modified small molecules
Dec, 2024

(1 year, 10 months from now)

Drugs and Companies using NALOXEGOL OXALATE ingredient

Market Authorisation Date: 16 September, 2014

Treatment: Treatment of opioid-induced constipation

Dosage: TABLET;ORAL

How can I launch a generic of MOVANTIK before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in